[Effects of bombesin and its antibody on growth of human prostatic carcinoma cell lines].
Bombesin (BMBS), a tetradecapeptide isolated from frog skin, and its antibody were evaluated in vitro and in vivo for their growth modulating effects on human prostatic carcinoma cell lines DU-145 and PC-3. The two cell lines were maintained in DME medium containing 2% FCS and 1 microgram/ml insulin in a humidified atmosphere of 5% CO2/95% air at 37 degrees C. BMBS added at 0.1-10.0 nM caused a striking shift of the concentration-dependent increase in cell growth of DU-145 and PC-3 in the absence of any other exogenously added growth factors. The addition of 1:250 antibody versus BMBS (Ab-BMBS; rabbit antiserum) to the medium during the lag phase of growth resulted in specific inhibition of growth of DU-145 and PC-3 with or without BMBS. Nude mice were transplanted with DU-145 cells in order to evaluate the suppressing qualities of Ab-BMBS on carcinoma cells in vivo. After the inoculation of 10(7) cells/mouse DU-145 into nude mice, 20 microliters/mouse Ab-BMBS was intraperitoneally injected into mice three times weekly for three weeks. In mice administrated with Ab-BMBS, the growth of DU-145 was suppressed markedly. By immunocytochemical study, BMBS immunoreactivities were detected on DU-145 and PC-3 cells. These results suggest that BMBS can function as an autocrine growth factor for human prostatic carcinoma cells. Furthermore, on xenografts in mice, Ab-BMBS inhibits the increase of human prostatic carcinoma.
Shimoda
J
J
Department of Urology, Akita University, School of Medicine.
D000818:Animals; D000906:Antibodies / Q000494:pharmacology* / Q000627:therapeutic use; D001839:Bombesin / Q000276:immunology / Q000494:pharmacology*; D002455:Cell Division / Q000187:drug effects*; D002478:Cells, Cultured; D004305:Dose-Response Relationship, Drug; D006801:Humans; D008297:Male; D051379:Mice; D009368:Neoplasm Transplantation; D011471:Prostatic Neoplasms / Q000188:drug therapy / Q000473:pathology*
D000906:Antibodies; D001839:Bombesin